In 2023, Flagship expanded its presence into Europe and Asia with hubs in London and Singapore to bridge Flagship’s primarily Boston-based ecosystem with these regional life sciences ecosystems and broaden our impact on human health and the health of our planet.
Flagship’s expansion into the UK, marked by the establishment of our London hub, reflects our recognition of the UK’s exceptional scientific ecosystem and its regulatory environment that supports a culture of innovation. The UK is home to world-renowned research institutions, cutting-edge biotech clusters, and a robust data ecosystem, making it a fertile ground for transformative breakthroughs. By embedding ourselves in this dynamic ecosystem, we aim to forge strategic partnerships with industry-leading academic and healthcare institutions, accelerating our global impact on human health. Since opening the hub, we announced an agreement with top life science organizations Cambridge University Health Partners and the Milner Therapeutics Institute to collaborate to jointly advance breakthrough scientific research and technologies.
The APAC region is home to premier research centers led by renowned scientists, consolidated large datasets, and pharma, tech, and manufacturing powerhouses, along with half the world’s population and GDP growth. Flagship’s expansion into APAC through our hub in Singapore is focused on building strategic partnerships across industry, academia, and healthcare systems, with an initial focus on Japan, South Korea and Singapore. Since opening the hub, we’ve announced new partnerships in the region including with The Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency.
Through these recent global efforts and further leveraging our expertise in constructing robust life sciences ecosystems, Flagship continues to explore the next frontier in applying its capabilities and know-how to empower emergent biotech ecosystems focused on human and planetary health.
Contacts:
